Navigation Links
The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Date:2/22/2010

ST. JOSEPH, Mich., Feb. 22 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that the Medical Biochemistry group at the Academic Medical Center, University of Amsterdam will join the MetaMiner Metabolic Diseases project from GeneGo. The MetaMiner program is focused on the fundamental understanding of human diseases at the level of disease pathways and causative gene-disease associations supported by a repository of OMICs data. Ongoing MetaMiner projects include Oncology, CNS, Cystic fibrosis and Stem cells.

"GeneGo provides unique, innovative reconstructions of disease pathways that are fundamentally important and required for the understanding of disease processes so we can find cures," said Milka Sokolovic, PhD, Medical Biochemistry, Academic Medical Center, Amsterdam. "We want to be a part of this innovation to have access to high quality resources to build pathways we need for our research programs that we will use to publish."

"The University of Amsterdam group is well known for their research on nutrition and fasting and we really welcome Milka's expertise in this area," said Julie Bryant, GeneGo's VP of Business Development. "This will be the first 'systems analysis' platform devoted specifically for metabolic diseases. We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.1, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

SOURCE GeneGo, Inc.

Back to top

RELATED LINKS
http://www.genego.com

'/>"/>

SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Canadian solar photovoltaic research network established; based at McMaster University
2. Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
3. Hahnemann University Hospital Granted Magnet(R) Status
4. Indiana Industry, University and Community Leaders Capitalize on Next Generation of States Life Sciences Growth
5. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
6. Nikon Corporation Acquires License From Harvard University For STORM Super Resolution Microscopy -- Will Create Innovative New N-STORM Microscope
7. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
8. iSirona Announces Go-live at University Hospitals in Cleveland
9. Arts Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia
10. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
11. New Program to Bring University of Florida Incubator Companies Millions in New Contracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a ... biotechnology industries to improve patient outcomes and quality of life, will now be ... are being attributed to new regulatory requirements for all new drug products, including ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):